Trial intelligence / Profile preview

CTC enumeration with Somatuline Autogel in functioning midgut neuroendocrine tumors

2013-002194-22Phase 4Completed

Sponsor: Ipsen
Start: Dec 2013
Modality: Peptides
Countries: 1

Overview

Phase 4, open-label, single-arm trial of lanreotide in apudoma (NET), sponsored by Ipsen. Primary endpoints: Clinical value of circulating tumour cell enumeration to predict clinical symptomatic response and Clinical symptomatic response. Started Dec 2013; status: completed.

Drugs

lanreotide

Conditions

apudoma (NET)

Beyond the preview

Go deeper on 2013-002194-22.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2013-002194-22.